Pooled estimates of clinical events in studies comparing DOACs vs warfarin in patients with concomitant valve disease and AF by repair/replacement status in non-RCTs
| . | Total patients, n . | OR, events per test period . | Heterogeneity . | |||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | Q test (P value) . | Higgins I2, % . | ||
| Overall bleeds | ||||||
| Repair/replacement | 33 111 | 0.84 | 0.59-1.20 | .34 | .01 | 63 |
| No repair/replacement | 71 071 | 0.59 | 0.36-0.98 | .04 | <.01 | 97 |
| Stroke incidence | ||||||
| Repair/replacement | 33 637 | 0.83 | 0.54-1.26 | .38 | .02 | 58 |
| No repair/replacement | 60 715 | 0.55 | 0.33-0.93 | .02 | <.01 | 96 |
| . | Total patients, n . | OR, events per test period . | Heterogeneity . | |||
|---|---|---|---|---|---|---|
| OR . | 95% CI . | P value . | Q test (P value) . | Higgins I2, % . | ||
| Overall bleeds | ||||||
| Repair/replacement | 33 111 | 0.84 | 0.59-1.20 | .34 | .01 | 63 |
| No repair/replacement | 71 071 | 0.59 | 0.36-0.98 | .04 | <.01 | 97 |
| Stroke incidence | ||||||
| Repair/replacement | 33 637 | 0.83 | 0.54-1.26 | .38 | .02 | 58 |
| No repair/replacement | 60 715 | 0.55 | 0.33-0.93 | .02 | <.01 | 96 |
The results represent a pooled estimate for all DOACs (apixaban, edoxaban, and rivaroxaban).